{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:02:41Z","timestamp":1791201761640,"version":"4.2.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.revmed.2012.11.008","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T17:02:29Z","timestamp":1356973349000},"page":"614-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Syndromes lipodystrophiques"],"prefix":"10.1016","volume":"34","author":[{"given":"L.","family":"Fardet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Capeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2012.11.008_bib0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the metabolic syndrome \u2013 an allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.revmed.2012.11.008_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000316893","article-title":"Human lipodystrophies: genetic and acquired diseases of adipose tissue","volume":"19","author":"Capeau","year":"2010","journal-title":"Endocr Dev"},{"key":"10.1016\/j.revmed.2012.11.008_bib0015","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: pathophysiology and advances in treatment","volume":"7","author":"Fiorenza","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0025","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.biocel.2011.03.002","article-title":"Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity","volume":"43","author":"Vigouroux","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0030","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1210\/jc.2003-030835","article-title":"Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2\u00a0or seipin genes","volume":"88","author":"Simha","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1651-2227.1996.tb14262.x","article-title":"Generalized lipodystrophy, congenital and acquired (lipoatrophy)","volume":"413","author":"Seip","year":"1996","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.revmed.2012.11.008_bib0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg.39.10.722","article-title":"Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy","volume":"39","author":"Van Maldergem","year":"2002","journal-title":"J Med Genet"},{"key":"10.1016\/j.revmed.2012.11.008_bib0045","first-page":"3077","article-title":"Postmortem findings in congenital generalized lipodystrophy","volume":"80","author":"Chandalia","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0050","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1073\/pnas.0308744101","article-title":"Serum leptin level is a regulator of bone mass","volume":"101","author":"Elefteriou","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2012.11.008_bib0055","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1210\/jc.2009-1824","article-title":"Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2\u00a0deficiency","volume":"95","author":"Antuna-Puente","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0060","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0065","first-page":"503","article-title":"Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes","volume":"83","author":"Pardini","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2337\/diacare.19.1.28","article-title":"Severe islet amyloidosis in congenital generalized lipodystrophy","volume":"19","author":"Garg","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.revmed.2012.11.008_bib0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000313932","article-title":"Effect of diet intervention and oral zinc supplementation on metabolic control in Berardinelli-Seip syndrome","volume":"57","author":"Dantas de Medeiros Rocha","year":"2010","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0080","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1542\/peds.2006-3165","article-title":"Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy","volume":"120","author":"Beltrand","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.revmed.2012.11.008_bib0085","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy","volume":"54","author":"Javor","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.revmed.2012.11.008_bib0090","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.biochi.2012.03.013","article-title":"Therapeutic use of recombinant methionyl human leptin","volume":"94","author":"Vatier","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.revmed.2012.11.008_bib0095","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/path.2999","article-title":"Nuclear lamins laminopathies","volume":"226","author":"Worman","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0100","first-page":"33","article-title":"Familial lipoatrophic diabetes with dominant transmission. A new syndrome","volume":"43","author":"Dunnigan","year":"1974","journal-title":"Q J Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0105","first-page":"170","article-title":"Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)","volume":"84","author":"Garg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0110","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2005.00234.x","article-title":"Hepatic steatosis in Dunnigan-type familial partial lipodystrophy","volume":"100","author":"L\u00fcdtke","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0115","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1210\/jc.2007-2521","article-title":"Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy","volume":"93","author":"Vantyghem","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0120","first-page":"1776","article-title":"Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)","volume":"85","author":"Garg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0125","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.2337\/diabetes.49.11.1958","article-title":"Lamin A\/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy","volume":"49","author":"Vigouroux","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.revmed.2012.11.008_bib0130","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1161\/01.CIR.103.18.2225","article-title":"Premature atherosclerosis associated with monogenic insulin resistance","volume":"103","author":"Hegele","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2012.11.008_bib0135","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1464-5491.2002.00796.x","article-title":"Post-mortem findings in familial partial lipodystrophy. Dunnigan variety","volume":"19","author":"Haque","year":"2002","journal-title":"Diabetes Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.revmed.2012.11.008_bib0145","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety","volume":"97","author":"Simha","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0150","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2012.11.008_bib0160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35\u00a0cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2012.11.008_bib0170","first-page":"343","article-title":"Renal disease in partial lipodystrophy","volume":"41","author":"Eisinger","year":"1972","journal-title":"Q J Med"},{"issue":"7828","key":"10.1016\/j.revmed.2012.11.008_bib0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(73)92351-9","article-title":"Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia","volume":"2","author":"Peters","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2012.11.008_bib0180","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/00126334-200212153-00011","article-title":"Relationship between HAART adherence and adipose tissue alterations","volume":"31","author":"Ammassari","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.revmed.2012.11.008_bib0185","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","article-title":"Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy","volume":"15","author":"Duran","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0190","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/383573","article-title":"Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1","volume":"38","author":"Blanch","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2012.11.008_bib0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9343(02)01156-7","article-title":"Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection","volume":"113","author":"Lenert","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0200","unstructured":"www.sante.gouv.fr\/IMG\/pdf\/Rapport_2010_sur_la_prise_en_charge_medicale_des_personnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni.pdf."},{"key":"10.1016\/j.revmed.2012.11.008_bib0205","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0210","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00126334-200209010-00007","article-title":"Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study","volume":"31","author":"Bernasconi","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.revmed.2012.11.008_bib0215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.revmed.2012.11.008_bib0220","first-page":"A38","article-title":"Prevalence of lipodystrophy among patients on antiretroviral therapy for up to 10\u00a0years. A french observational study","volume":"15","author":"Leclercq","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.revmed.2012.11.008_bib0225","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00002030-200101260-00024","article-title":"Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection","volume":"15","author":"Goujard","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0230","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2012.11.008_bib0235","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.aids.0000131334.38172.01","article-title":"Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe","volume":"18","author":"European Paediatric Lipodystrophy Group","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0240","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/ije\/31.5.1016","article-title":"Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy","volume":"31","author":"Heath","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1464-2662.2001.00100.x","article-title":"Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3\u00a0years of antiretroviral treatment","volume":"3","author":"Mauss","year":"2002","journal-title":"HIV Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0250","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0255","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2012.11.008_bib0260","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1258\/ijsa.2010.010256","article-title":"Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755\u00a0adult patients with HIV-1\u00a0infection","volume":"22","author":"Calza","year":"2011","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0265","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2334-12-180","article-title":"Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance","volume":"12","author":"Freitas","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.revmed.2012.11.008_bib0270","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/QAI.0b013e31819c291b","article-title":"Prevalence and pathogenesis of diabetes mellitus in HIV-1\u00a0infection treated with combined antiretroviral therapy","volume":"50","author":"Samaras","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.revmed.2012.11.008_bib0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/QAD.0b013e32834e8776","article-title":"Ten-year diabetes incidence in 1046\u00a0HIV-infected patients started on a combination antiretroviral treatment","volume":"26","author":"Capeau","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0280","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/135965350501000706","article-title":"Predictors of hypertension and changes of blood pressure in HIV-infected patients","volume":"10","author":"Thi\u00e9baut","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.revmed.2012.11.008_bib0285","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/00004872-200307000-00028","article-title":"Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome","volume":"21","author":"Gazzaruso","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.revmed.2012.11.008_bib0290","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0295","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/09540121.2010.543885","article-title":"Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study","volume":"23","author":"Lake","year":"2011","journal-title":"AIDS Care"},{"key":"10.1016\/j.revmed.2012.11.008_bib0300","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0149-2918(03)80283-7","article-title":"An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy","volume":"25","author":"Barbaro","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.revmed.2012.11.008_bib0305","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/00002030-200211080-00011","article-title":"Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy","volume":"16","author":"Sutinen","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2012.11.008_bib0310","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/367859","article-title":"Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin","volume":"36","author":"Nagy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2012.11.008_bib0315","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/jc.2005-1545","article-title":"Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0320","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2008-1588","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia","volume":"94","author":"Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0325","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","article-title":"Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension","volume":"53","author":"Falutz","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.revmed.2012.11.008_bib0330","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0248-8663(97)82511-8","article-title":"Les lipomatoses induites par la corticoth\u00e9rapie","volume":"18","author":"Humblot","year":"1997","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2012.11.008_bib0335","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/eje.0.1490561","article-title":"Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome","volume":"149","author":"Rockall","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0340","first-page":"2791","article-title":"Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease","volume":"80","author":"Wajchenberg","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0345","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0039-128X(03)00086-2","article-title":"Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound","volume":"68","author":"Schou","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.revmed.2012.11.008_bib0350","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2265.2010.03829.x","article-title":"MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease","volume":"73","author":"Geer","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.revmed.2012.11.008_bib0355","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: frequency risk factors patient's opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0360","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF03345125","article-title":"Clinical laboratory findings and results of therapy in 55\u00a0patients with Cushing's syndrome","volume":"26","author":"Erem","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.revmed.2012.11.008_bib0365","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2265.2000.01117.x","article-title":"How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?","volume":"53","author":"Kaltsas","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.revmed.2012.11.008_bib0370","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1525-1470.1998.1998015253.x","article-title":"Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia","volume":"15","author":"Stratakis","year":"1998","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0375","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2133.2010.09877.x","article-title":"Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy","volume":"163","author":"Arena","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0380","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.revmed.2011.02.022","article-title":"Description des prescriptions de corticoth\u00e9rapies orales en population g\u00e9n\u00e9rale","volume":"32","author":"Fardet","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2012.11.008_bib0385","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mai.2000.109830","article-title":"Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma","volume":"106","author":"Covar","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0390","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/09546634.2010.487887","article-title":"Comparative study of the effect of a daily steroid regimen versus a weekly oral pulse steroid regimen on morphological changes, blood sugar, bone mineral density and suprarenal gland activity","volume":"23","author":"El-Darouti","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.revmed.2012.11.008_bib0395","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0400","first-page":"55","article-title":"A clinico-pathological study of Cushing's syndrome at the University Hospital of the West Indies and a review of the literature","volume":"50","author":"Wright-Pascoe","year":"2001","journal-title":"West Indian Med J"},{"key":"10.1016\/j.revmed.2012.11.008_bib0405","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.04.018","article-title":"Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study","volume":"57","author":"Fardet","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0410","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2012.11.008_bib0415","doi-asserted-by":"crossref","unstructured":"Fardet L, Antuna-Puente B, Vatier C, Cervera P, Touati A, Simon T, et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf). doi: 10.1111\/j.1365-2265.2012.04348.x.","DOI":"10.1111\/j.1365-2265.2012.04348.x"},{"key":"10.1016\/j.revmed.2012.11.008_bib0420","first-page":"5301","article-title":"Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome","volume":"86","author":"Garrapa","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0425","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kem062","article-title":"Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome","volume":"46","author":"Fardet","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2012.11.008_bib0430","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing's disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0435","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.revmed.2012.11.008_bib0440","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2012.11.008_bib0445","doi-asserted-by":"crossref","first-page":"e4928","DOI":"10.1136\/bmj.e4928","article-title":"Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study","volume":"345","author":"Fardet","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2012.11.008_bib0450","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/eje.0.1490543","article-title":"Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography","volume":"149","author":"Rockall","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.revmed.2012.11.008_bib0455","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000318505","article-title":"Diagnosis of cure in Cushing's syndrome: lessons from long-term follow-up","volume":"38","author":"Barahona","year":"2010","journal-title":"Front Horm Res"},{"key":"10.1016\/j.revmed.2012.11.008_bib0460","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1210\/jc.2009-0766","article-title":"Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome","volume":"94","author":"Barahona","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2012.11.008_bib0465","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.revmed.2007.06.002","article-title":"Histoire naturelle de la lipodystrophie cervicofaciale cortico-induite: suivi prospectif d\u2019une cohorte de 37\u00a0patients","volume":"28","author":"Fardet","year":"2007","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2012.11.008_bib0470","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s12020-012-9742-8","article-title":"Cushingoid lipodystrophy can be prevented by thiazolidinediones","volume":"42","author":"Winkel","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.revmed.2012.11.008_bib0475","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ijo.2009.286","article-title":"Gluteofemoral body fat as a determinant of metabolic health","volume":"34","author":"Manolopoulos","year":"2010","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.revmed.2012.11.008_bib0480","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/JOE-10-0272","article-title":"Lipodystrophy: metabolic insights from a rare disorder","volume":"207","author":"Huang-Doran","year":"2010","journal-title":"J Endocrinol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866312011496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866312011496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:32:47Z","timestamp":1759336367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866312011496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":96,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0248866312011496"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2012.11.008","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndromes lipodystrophiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2012.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}